HCM
MRVI icon

Harspring Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Harspring Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500,000
Closed -$1.21M – 17
2025
Q2 		$1.21M Buy
+500,000
New +$1.05M 0.42% 17

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Harspring Capital Management's MRVI Position: Q3 2025 in Review

Harspring Capital Management sold out of Maravai LifeSciences (MRVI) in Q3 2025, closing a stake of 500,000 shares — an estimated $1.21M sold.

Harspring Capital Management first reported a position in MRVI in Q2 2025 and held it in 1 quarter. The position peaked at $1.21M in Q2 2025. 160 funds tracked by Wall St. Rank hold MRVI as of Q3 2025.

  • Harspring Capital Management reported no remaining Maravai LifeSciences position as of Q3 2025 after selling out during the quarter.
  • Harspring Capital Management sold 500,000 Maravai LifeSciences shares in Q3 2025, an estimated $1.21M.
  • Harspring Capital Management first reported a position in Maravai LifeSciences in Q2 2025 and held it in 1 quarter.
  • Harspring Capital Management's Maravai LifeSciences position peaked at $1.21M in Q2 2025.
  • 160 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2025.

Based on Harspring Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.